Canopy Growth restructures, focuses on medical cannabis to recover from losses

Canopy Growth has begun to show signs of recovery after years of financial turmoil. The cannabis company, once a giant in the industry, has seen its stock plummet more than 99% from its all-time high. After burning through billions, diluting shares, and restructuring multiple times, Canopy is now focusing on stabilizing its balance sheet and improving its fundamentals.

The shift comes amid a broader reevaluation of its business strategy. Canopy previously pursued aggressive global expansion, investing heavily in production and acquiring various companies. This approach backfired, leading to significant losses. However, management has now adopted a more disciplined stance. The company has exited non-core businesses, including its sports nutrition brand BioSteel, and streamlined its operations to focus on higher-margin medical cannabis markets. Recent efforts also included the acquisition of MTL Cannabis, bolstering its presence in both recreational and medical sectors.

Financially, Canopy's situation is gradually improving. Earlier this year, the company completed a significant recapitalization that relieved some of its debt burden. By the end of fiscal 2026, Canopy reported around $131.3 million in net cash, providing the company with more financial flexibility. While it still struggles to achieve consistent profitability, the improved cash position allows management to focus on operational enhancements rather than mere survival.

Looking ahead, Canopy is redirecting its growth strategy towards the medical cannabis market, which presents a more promising landscape compared to Canada's competitive recreational sector. As the company continues to stabilize, its ability to navigate this transition could determine whether it emerges as a leader in the medical cannabis space or remains trapped in its past misfortunes.